Madrigal Pharmaceuticals, Inc. (1MDGL.MI)
Milan · EUR · Healthcare · Biotechnology
€440.10 (-1.30%) as of
Key statistics
- Market cap
- 10.17B
- EPS (TTM)
- -11.02
- Dividend yield
- 0.00%
- 52-week range
- 349.10 – 498.30
- Beta
- -1.05
- Revenue (TTM)
- 1.28B
- Profit margin
- -25.32%
- Volume
- 7.00
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- West Conshohocken, PA, United States
- Employees
- 915
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.